Rice Hall James & Associates’s UroGen Pharma URGN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.14M	Buy	285,834 +3,958	+1%	+$79.4K	0.29%	83
2025 Q4	$6.6M	Buy	281,876 +22,733	+9%	+$493K	0.36%	68
2025 Q3	$5.17M	Sell	259,143 -28,731	-10%	-$516K	0.28%	84
2025 Q2	$3.94M	Buy	287,874 +32,083	+13%	+$308K	0.21%	100
2025 Q1	$2.83M	Sell	255,791 -8,240	-3%	-$87.9K	0.17%	130
2024 Q4	$2.81M	Sell	264,031 -7,866	-3%	-$94.2K	0.15%	145
2024 Q3	$3.45M	Buy	271,897 +199,110	+274%	+$2.96M	0.19%	123
2024 Q2	$1.22M	Buy	72,787 +2,381	+3%	+$33.9K	0.07%	197
2024 Q1	$1.06M	Buy	70,406 +514	+0.7%	+$8.4K	0.06%	208
2023 Q4	$1.05M	Sell	69,892 -5,288	-7%	-$68.6K	0.06%	214
2023 Q3	$1.05M	Sell	75,180 -907	-1%	-$14.6K	0.07%	202
2023 Q2	$788K	Buy	76,087 +2,882	+4%	+$31.8K	0.04%	230
2023 Q1	$676K	Buy	73,205 +274	+0.4%	+$2.52K	0.04%	240
2022 Q4	$647K	Sell	72,931 -1,500	-2%	-$14.2K	0.04%	242
2022 Q3	$619K	Sell	74,431 -36,026	-33%	-$298K	0.04%	242
2022 Q2	$905K	Buy	110,457 +2,467	+2%	+$16.9K	0.04%	231
2022 Q1	$941K	Buy	107,990 +6,631	+7%	+$51.7K	0.04%	242
2021 Q4	$964K	Sell	101,359 -47,901	-32%	-$675K	0.03%	246
2021 Q3	$2.51M	Sell	149,260 -92,377	-38%	-$1.46M	0.09%	170
2021 Q2	$3.69M	Sell	241,637 -45,168	-16%	-$817K	0.13%	119
2021 Q1	$5.59M	Buy	286,805 +184,752	+181%	+$3.92M	0.18%	101
2020 Q4	$1.84M	Buy	+102,053	New	+$2.14M	0.06%	208